Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Deals channel feed
Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio
Last month
China
Pharma
Retro Biosciences inks blood disorder deal as Sam Altman-backed biotech seeks $1B in funds
Last month
Startups
Cell/Gene Tx
Why Regeneron is buying 23andMe
Last month
Regeneron plans to buy 23andMe for $256M
Last month
Pharma
BioMarin makes Phase 3 buy, paying $270M for rare disease outfit Inozyme
Last month
Pharma
Eli Lilly turns to South Korean RNA editing biotech for hearing loss in deal worth $1.3B
Last month
Startups
Cell/Gene Tx
Exclusive: Datavant to acquire real-world data specialist Aetion, doubling life sciences team
Last month
AI
AbbVie doubles down on siRNA with $335M upfront bet on ADARx
Last month
Startups
Pharma
GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope
Last month
Pharma
Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B
Last month
Pharma
Cedars-Sinai partners with Redesign Health to build health tech startups
2 months ago
Health Tech
Exclusive: SEC expected to drop investigation of Illumina's $8B Grail deal
2 months ago
Diagnostics
Law
Function buys Ezra, creating one-stop shop for preventive testing and scans
2 months ago
Startups
Health Tech
After hunt for alternatives, Kronos Bio selects Tang Capital's Concentra for a deal
2 months ago
Amicus grabs Dimerix’s rare kidney disease drug for $30M upfront
2 months ago
Pharma
Teladoc buys virtual therapy startup UpLift for $30M
2 months ago
Health Tech
Updated: Novartis to buy Regulus Therapeutics for up to $1.7B
2 months ago
Pharma
Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B
2 months ago
Pharma
New fund will pressure flailing biotechs, as investor frustration boils over
2 months ago
Financing
Merck KGaA closes in on SpringWorks deal at $3.5B price point
2 months ago
Pharma
Bristol Myers CEO signals dealmaking will be a top priority in 2025
2 months ago
Pharma
Roche CEO warns that tariffs could impact dealmaking
2 months ago
Pharma
China’s biotech market is staging a comeback that US biotech can only wish for
2 months ago
China
Repertoire inks autoimmune deal with Genentech as it eyes a return to the clinic
2 months ago
Startups
Pharma
First page
Previous page
1
2
3
4
5
6
Next page
Last page
